Summit Securities Group’s Travere Therapeutics TVTX Stock Holding History

Summit Securities Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-19	Closed	–	–	799
2014 Q2	$0	Buy	+19	New	+$257	﹤0.01%	651

Other funds holding TVTX

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

Summit Securities Group's TVTX Position: Q3 2014 in Review

Summit Securities Group sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 19 shares.

Summit Securities Group first reported a position in TVTX in Q2 2014 and held it in 1 quarter. The position peaked at $0 in Q2 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

Summit Securities Group reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
Summit Securities Group sold 19 Travere Therapeutics shares in Q3 2014.
Summit Securities Group first reported a position in Travere Therapeutics in Q2 2014 and held it in 1 quarter.
Summit Securities Group's Travere Therapeutics position peaked at $0 in Q2 2014.
60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on Summit Securities Group's 13F filing for Q3 2014, filed 13 Nov 2014.